Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Emily MenendezAdvanced Renal Cell Carcinoma | January 29, 2025
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Read More
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | January 22, 2025
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Jihad Kaouk, MDLocalized Renal Cell Carcinoma | January 21, 2025
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Jose A. Karam, MD, FACSLocalized Renal Cell Carcinoma | January 21, 2025
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Emily MenendeznccRCC | January 16, 2025
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
Emily MenendezAdvanced Renal Cell Carcinoma | January 14, 2025
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Emily MenendezLocalized Renal Cell Carcinoma | January 8, 2025
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
Emily MenendezRenal Cell Carcinoma Diagnostics | January 3, 2025
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Zachary BessetteRenal Cell Carcinoma | January 2, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Laurence Albiges, MD, PhDAdvanced Renal Cell Carcinoma | January 2, 2025
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Laurence Albiges, MD, PhDAdvanced Renal Cell Carcinoma | January 2, 2025
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | January 9, 2025
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | December 19, 2024
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Yvette C. TerrieRenal Cell Carcinoma Diagnostics | December 16, 2024
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Yvette C. TerrieRenal Cell Carcinoma | December 9, 2024
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
Yvette C. TerrienccRCC | December 9, 2024
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
Regina Barragan-Carrillo, MDAdvanced Renal Cell Carcinoma | December 5, 2024
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Kaitlyn KoskoRenal Cell Carcinoma Diagnostics | December 5, 2024
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Advertisement
Advertisement
Advertisement